While our study suggests similar clinical effects of PD-1 plus chemotherapy and PD-L1 plus chemotherapy, caution is warranted in utilizing PD-1 plus chemotherapy as first-line treatment for ES-SCLC [24]. The gene discussed is PDCD1; the disease is small cell lung carcinoma.